Dr. Gertraud Orend is currently working as group leader at the University of Strasbourg, France. Dr. Orend received her PhD in Genetics from the University of Cologne, Germany. She then worked as postdoc at the Burnham Institute, La Jolla, California, USA, and served as Associate Professor and Senior scientist at the University Basel, Switzerland and at INSERM in Strasbourg, France. Dr. Orend has authored more than 50 highly cited publications that reflect her research interests in the field of extracellular matrix. Dr. Orend is a member of the International and French societies of Matrix Biology.
Stefan Gluck, MD, PhD, FRCPC is medical oncologist and V.P. Global Medical Affairs, at Celgene Corporation since October 2014. He oversees oncology activities worldwide, as well as the Immuno-Oncology program in solid tumors and hematology. He also contributes to activities of Celgene around Early Assets. He previously served as a Sylvester Professor in the Department of Medicine at Miller School of Medicine, University of Miami, Florida until September 2014. From 2003-2008, he was the Clinical Director of the Braman Family Breast Cancer Institute, and from January 2009 - December 2010 Assistant Director of the Sylvester Comprehensive Cancer Center and Associate Chief, Division Hematology & Medical Oncology. He has been a PI of 37 clinical studies of breast cancer in Miami, as well as investigator in numerous scientific, translational projects.
Hani M. Al-Afghani Clinical Laboratory Supervisor
The Comprehensive Specialized Clinics for the Security Forces, Saudi Arabia
Dr Hani Currently Hani Al-Afghani working as a clinical laboratory supervisor within the comprehensive specialized clinics. Working within a research team interestedincancergenetics and hereditary haematology disorders. His research skills and hardworking behaviours together with magnificent results have allowed to be awarded with award of excellence in kidney disease in 2002. Also have awarded with award of excellence in cancer research in 2015. He Involved with different symposiums regarding topics that include different issues about medical genetics. Recently, He have led the scientific organizational committee of the 14th medical genetics workshop in Makkah, Saudi Arabia. Personally worked on a project on cancer of both medulloblastoma and colorectal cancer. He is an editorial member in three scientific journals. Also, he was a member of scientific and organizing committee in the 3rd world congress of Cancer science and Immunology. He has a membership in Saudi Society of Medical Genetics.
Catherine Paul is Associate Professor at the Ecole Pratique des Hautes Etudes. She received her PhD on 2001 from the Claude Bernard University, Lyon I. She works in the field of cancer immunology and immunotherapy at the University of Burgundy in Dijon. Her current work focuses on the role of nitric oxide (NO) as an anti-cancer agent when combined with other therapeutic molecules. Her research falls within the framework of translational research in oncology.
Shaoying Li Associate Professor
University of Texas MD Anderson Cancer Center, USA
Dr. Shaoying Li has received her MD from Beijing Medical University (Current name: Peking University Health Science Center). She is currently an associate professor in the Department of Hematopathology at the University of Texas MD Anderson Cancer Center. She is board certified by the American Board of Pathology in Anatomic Pathology, Clinical Pathology, and Hematology. In addition to clinical responsibilities on Lymphoma, leukemia, myeloma and flow cytometry services, Dr. Li has been actively participating in multiple research projects in lymphoma and leukemia, which has led to over 100 research papers and multiple book chapters. She also serves as members of editorial boards and ad hoc reviewers for multiple journals. Her major research interests include molecular cytogenetic risk stratification of DLBCL with a focus on "double hit" lymphoma and MYC/BCL2 double expresser lymphoma, clinicopathologic and molecular study of mantle cell lymphoma, and molecular genetic aberrations in lymphoma and leukemia.
Abdolrahman Shams Nateri is Associate Professor & Group Leader of Cancer Genetics and Stem Cell Laboratory, at the School of Medicine, and University of Nottingham, UK. He received his PhD in 2001 from the Essex University. He then joined Cancer Research UK London Research Institute (LRI, Axel Behrens's laboratory), where he carried out basic-research into the links between transcriptions, MAPKs signalling & diseases, including the cellular/molecular biology of cancer. His laboratory in Nottingham investigates how signalling pathways integrate their action to affect cell specific fates in healthy and cancer tissues, by modelling the tumour microenvironment. In particular, the molecular and cellular pathways that are involved in regulating the development of cancer stem-like cell (CSC) populations and CSC-targeted therapeutic strategies aiming to eradicate malignancies.
Dr. Peiying Yang is a Tenured Associate Professor at Department of Palliative, Rehabilitation and Integrative Medicine at the University of Texas MD Anderson Cancer Centre. She received her undergraduate and master degree in Pharmacy from the Beijing University of Traditional Chinese Medicine. Following a year and half of study in Department of Pharmaceutical Science at University of Kentucky, College of Pharmacy, she completed her Doctor degree in Nutritional Science from the University of Maine.